FREDUN PHARMACEUTICALS LIMITED
Compassionate Healthcare
CIN No: L24239MH1987PLC043662

Date: 05th November, 2026

To,
BSE Limited
Listing Department,
Phiroze Jeejeebhoy Towers,
Dalal Street - Fort,
Mumbai — 400 001.

Ref.: BSE Scrip Code - 539730

Subject: Outcome of the Board Meeting

Dear Sir / Madam,

Pursuant to Regulations 30 and 33 of SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015 we wish to inform you that the Board of Directors of the Company at its meeting held today i.e. Thursday, November 05, 2026 has inter-alia, considered, adopted and approved following items of business:

1. In compliance to Regulation 30 and 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the Un-Audited Financial Results of the Company for the Quarter and Half-Year Ended 30th September, 2026 along with the Limited Review Report as issued by M/s. R.H. Nisar & Co, Statutory Auditor of the Company; copies of which are attached hereunder;

2. The Board considered and approved the proposal for making an application to National Stock Exchange of India Limited (NSE) for listing and trading of the equity shares of the Company on NSE, subject to applicable laws, regulations and the necessary approvals.

   In furtherance to the intimation filed by the Company dated November 28, 2026 the trading window for trading in securities of the Company by insiders closed on October 01, 2026 till the end of 48 hours after the declaration of outcome of this Board Meeting.

The Board Meeting commenced at 10:00 a.m. and concluded at 11:10 a.m.

Kindly oblige and take the same on your Records.

Thanking you,

FOR FREDUN PHARMACEUTICALS LIMITED

FREDUN NARIMAN MEDHORA
Digitally signed by FREDUN NARIMAN MEDHORA
Date: 2026.11.05 11:16:53 +05'30'

FREDUN NARIMAN MEDHORA
MANAGING DIRECTOR
DIN: 01745348

FREDUN PHARMACEUTICALS LIMITED

Compassionate Healthcare

CIN No : L24239MH1987PLC043662

UNAUDITED STANDALONE FINANCIAL RESULTS FOR THE QUARTER & HALF YEAR ENDED 30.09.2026

	PARTICULARS	Standalone					
		Quarter Ended			Half Year Ended		Year Ended
		Unaudited			Unaudited		Audited
		30.09.2026	30.06.2026	30.09.2025	30.09.2026	30.09.2025	31.03.2026
		Rs. In Lakhs	Rs. In Lakhs	Rs. In Lakhs	Rs. In Lakhs	Rs. In Lakhs	Rs. In Lakhs
1	**Income from Operations**						
	Net Sales /IncomeFrom Operation (Net of GST)	26585.36	22775.55	14358.53	49360.91	26298.82	63332.65
2	Other Operating Income	178.14	49.24	170.61	227.38	215.82	579.52
3	Total income from operatoins (net)	26763.50	22824.79	14529.14	49588.29	26514.64	63912.17
4	**Expenses**						
	a) Cost of Material Consumed	23981.10	17846.48	9925.75	41827.58	18958.37	48075.96
	b) Cost of Material Consumed for R & D	140.27	126.14	118.32	266.41	193.79	507.77
	c) Other R & D Expenses	0.00	0.00	0.00	0.00	0.00	0.00
	d) Changes in inventories of finished goods, work-in-progress and stock in trade	(4773.68)	(635.05)	441.29	(5408.73)	(224.85)	(3169.31)
	e) Manufacturing & Service Cost	448.70	407.35	366.13	856.05	730.04	1566.91
	f) Finance Costs	877.62	861.81	773.13	1739.43	1426.30	3929.76
	g) Employess benefits expenses	911.04	712.08	829.88	1623.12	1593.27	3294.34
	h) Depreciation and amortisation expenses	392.33	357.09	159.80	749.42	301.71	791.38
	i) Other Expenses	1795.86	1090.12	614.25	2885.98	1331.38	4157.16
	Total expenses	23773.24	20766.02	13228.55	44539.26	24310.01	59153.97
5	Profit/(Loss) from ordinary activities before exceptional items & tax (3-4)	2990.26	2058.77	1300.59	5049.03	2204.63	4758.20
6	Exceptional items / Prior Period Item	0.00	0.00	0.00	0.00	0.00	0.00
7	Profit/(Loss) from ordinary activities before tax (5-6)	2990.26	2058.77	1300.59	5049.03	2204.63	4758.20
8	Tax Expenses	1107.69	741.96	327.36	1849.65	554.82	1437.51
9	Profit/(Loss) from continuing operations	1882.57	1316.81	973.23	3199.38	1649.81	3320.69
10	Profit/(Loss) from discontinued operations	0.00	0.00	0.00	0.00	0.00	0.00
11	Tax Expense of discontinued operations	0.00	0.00	0.00	0.00	0.00	0.00
12	Profit/(Loss) from discontinued operations after tax	0.00	0.00	0.00	0.00	0.00	0.00
13	Profit/ (Loss) for the period	1882.57	1316.81	973.23	3199.38	1649.81	3320.69
14	Other comprehensive Income						
	A (i) Items that will not be re-classified to profit/ loss	0.00	0.00	0.00	0.00	0.00	0.00
	(ii) Income tax relating to items that will not be re-classified to profit/ loss	0.00	0.00	0.00	0.00	0.00	0.00
	B (i) Re measurement of post - employment benefit obligations	0.00	0.00	0.00	0.00	0.00	16.55
	C (i) Items that will be re-classified to profit / loss	0.00	0.00	0.00	0.00	0.00	0.00
	(ii) Income tax relating to items that will be re-classified to profit/ loss	0.00	0.00	0.00	0.00	0.00	0.00
	Total Comprehensive Income for the year	1882.57	1316.81	973.23	3199.38	1649.81	3337.24

FREDUN PHARMACEUTICALS LTD. MUMBAI

Registered Office: Urmi Estate, 11th Floor, Ganpatrao Kadam Marg, Lower Parel (W), Mumbai - 400013.
Phone No.: 91-22- 4031 8111 Fax: 91-22-4031 8133
Factory: 14,15,16, Zorabian Industrial Complex, Vevoor, Palghar (E), Dist: Palghar - 401 404.
Phone No.: +917045957828, +917045957829, +917045957830, +917045956857
E-Mail: business@fredungroup.com Web: www.fredungroup.com

FREDUN PHARMACEUTICALS LIMITED

Compassionate Healthcare

CIN No : L24239MH1987PLC043662

PARTICULARS	Standalone					
	Quarter Ended			Half Year Ended		Year Ended
	Unaudited			Unaudited		Audited
	30.09.2026	30.06.2026	30.09.2025	30.09.2026	30.09.2025	31.03.2026
	Rs. In Lakhs	Rs. In Lakhs	Rs. In Lakhs	Rs. In Lakhs	Rs. In Lakhs	Rs. In Lakhs
Paid up Equity Share Capital (Face Value of Rs-10/- each)	1689.97	1653.81	1416.51	1689.97	1416.51	1641.81
Reserves excluding Revaluation Reserves	0.00	0.00	0.00	0.00	0.00	0.00
Earning per Share (EPS) (before & after extra ordinary items)						
- Basic/ Diluted Earning Per Share (Rs.)	11.21	7.96	6.87	19.05	11.65	20.33
- Diluted Earning Per Share (Rs.)	11.07	7.87	0.00	18.81	0.00	19.92
1) Public Shareholding						
Number of shares	9528510	3055637	2411277	9528510	2411277	3055637
Percentage of shareholding	56.38%	55.43%	51.07%	56.38%	51.07%	55.83%
2) Promoters and promotor group shareholding						
a) Pledged/Encumbured						
- Number of shares	-	-	-	-	-	-
- Percentage of shares (as a % of total shareholding of Promoters and Prompter Group)	-	-	-	-	-	-
- Percentage of shares (as a % of total share capital of the Company)	-	-	-	-	-	-
b) Non-encumbered						
- Number of shares	7371159	2457053	2310385	7371159	2310385	2417053
- Percentage of shares (as a % of total shareholding of Promoters and Prompter Group)	43.62%	44.57%	48.93%	43.62%	48.93%	44.17%
- Percentage of shares (as a % of total share capital of the Company)	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%

TES:-

The above unaudited Standalone financial results which are published in accordance with Regulation 33 of the SEBI {Listing Obligations & Disclosure Requirements) Regulations, 2015 have been reviewed by the Audit Committee and approved by the Board of Directors at their respective meetings held on November 05, 2026. These unaudited Standalone financial results have been prepared in accordance with recognition and measurement principles of Indian Accounting Standards {"Ind AS") as prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and the other accounting principles generally accepted in India.

The above unaudited Standalone Financial results for the quarter ended September 30, 2026 are prepared in compliance with the Ind AS which have been subjected to a limited review by the statutory auditors of the Company. The statutory auditors, Rakesh Nisar & Co have issued limited review reports with unmodified conclusion on the standalone and consolidated unaudited financial results.

As the Company's business activity falls within a single operating segment viz "Pharmaceutical and Healthcare", no segment

The figures for the quarter ended Sept 30, 2026 are the balancing figures between audited figures in respect of the full financial year and the published year to date unaudited figures upto the third quarter of the previous financial year.

The figures for the earlier periods have been regrouped/ reclassified wherever necessary to make them comparable with those of the current period.

The above results were reviewed and recommended by the Audit Committee, for approval by the Board, at its meeting held on November 05, 2026 and were approved and taken on record at the meeting of the Board of Directors of the company held on that date

During the period, the Company allotted 11025380 fully paid-up bonus equity shares of ₹10 each in the ratio of two equity shares for every one equity share held, on 16.07.2026. Accordingly, basic and diluted earnings per share for all comparative periods presented have been retrospectively adjusted in accordance with Ind AS 33, "Earnings per Share." Earnings per share for the quarterly and half-yearly periods are not annualised.

During the half-year, the Company allotted 160533 equity shares pursuant to conversion of 160533 warrants, against receipt of the applicable consideration. The resulting increase in paid-up equity share capital has been reflected in these results. Basic and diluted earnings per share have been calculated considering the applicable weighted-average shares and dilutive potential equity shares.

FOR FREDUN PHARMACEUTICALS LIMITED

Dr. (Mrs) DAULAT N. MEDHORA
Chair Person & Joint Managing Director
DIN :01745277

FREDUN PHARMACEUTICALS LTD. MUMBAI

ICE: MUMBAI

TE : 05th November , 2026

Registered Office: Urmi Estate, 11th Floor, Ganpatrao Kadam Marg, Lower Parel (W), Mumbai - 400013.
Phone No.: 91-22- 4031 8111 Fax: 91-22-4031 8133
Factory: 14,15,16, Zorabian Industrial Complex, Vevoor, Palghar (E), Dist: Palghar - 401 404.
Phone No.: +917045957828, +917045957829, +917045957830, +917045956857
E-Mail: business@fredungroup.com Web: www.fredungroup.com

FREDUN PHARMACEUTICALS LIMITED

Standalone Balance Sheet for the Half Year Ended 30th Sept, 2026 **(Amount In Lakhs)**

			Notes	As at 30th Sept, 2026	As at 31st March, 2026
I	**ASSETS**				
	NON-CURRENT ASSETS				
	a)	Property, Plant and Equipment	3	14,825.90	11,760.54
	b)	Other Intangible Assets	4	69.42	62.94
	c)	Financial assets			
		i) Investments	5	254.23	201.73
		ii) Other Financial Assets	6	2,945.52	1,596.00
	d)	Other Non-current Assets	7	2,649.10	805.04
		Total non - current assets		**20,744.16**	**14,426.25**
	CURRENT ASSETS				
	a)	Inventories	8	37,244.77	26,980.45
	b)	Financial Assets			
		i) Trade and other receivables	9	9,703.33	9,268.52
		ii) Cash and Cash Equivalents	10	515.14	6,490.41
		iii) Bank Balance other than (iii) above	11	5.43	4.91
		iv) Loans	12	124.03	99.78
		v) Other Financial Assets	13	1,317.17	5,325.71
	c)	Other Current Assets	14	2,146.23	1,525.34
		Total current assets		**56,056.11**	**49,695.11**
		TOTAL ASSESTS		**76,800.27**	**64,121.36**
II	**EQUITY AND LIABILITIES**				
	EQUITY				
	a)	Equity share capital	15	1,689.97	547.27
	b)	Other equity	16	31,442.00	27,323.90
		Total Equity		**33,131.96**	**27,871.17**
	LIABILITIES				
	Non-Current Liabilities				
	a)	Financial liabilities			
		i) Borrowings	17	8,693.39	5,631.03
	b)	Provisions	18	418.46	425.55
	c)	Deferred Tax Liability		1,127.45	654.80
		Total non current - liabilities		**10,239.30**	**6,711.37**
	Current Liabilities				
	a)	Financial liabilities			
		i) Borrowings	19	15,971.46	16,572.03
		ii) Trade and other payable	20	12,231.72	8,746.68
		iii) Other financial liabilities	21	5.43	4.85
	b)	Other current liabilities	22	3,903.41	3,261.19
	c)	Current tax liabilities (net)	23	1,317.00	954.07
		Total current liabilities		**33,429.01**	**29,538.82**
		TOTAL EQUITY & LIABILITIES		**76,800.27**	**64,121.36**

For and on behalf of the Board of Directors of Fredun Pharmaceuticals Limited

CIN No - L24239MH1987PLC043662

For Fredun Pharmaceuticals Limited

FREDUN PHARMACEUTICALS LTD. MUMBAI

Dr. (Mrs) Daulat N.Medhora
Joint Managing Director
DIN : 01745277

MR. Fredun N. Medhora
Managing Director & CFO
DIN :01745348

Place - Mumbai
Date :- 05th November 2026

FREDUN PHARMACEUTICALS LIMITED

Compassionate Healthcare

CIN No : L24239MH1987PLC043662

	FREDUN PHARMACEUTICALS LIMITED				
	STANDALONE CASH FLOW STATEMENT FOR THE HALF YEAR ENDED 30th Sept, 2026				
		As at 30th Sept 2026		**As at 30th Sept 2025**	
		(Amount in Lakhs)		**(Amount in Lakhs)**	
A)	**Cash Flow From Operating Activities:**				
	Net Profit After Taxation		3,199.38		1,649.80
	Adjustments For :				
	Depreciation	749.42		301.71	
	Interest Paid	1,739.43		1,426.30	
	Interest Received	-26.26		4.49	
	Creditors Written Back	-68.49		-	
			2,394.10		1,732.50
			5,593.48		3,382.30
	Adjustment To Operating Profit				
	Deffered Tax Liability		472.65		34.08
	Adjustment For Tax Provision		1,377.00		-
	Operating Profit Before Working Capital Changes		7,443.13		3,416.38
	Effects Of Changes In Working Capital Items				
	Increase / Decrease In :-				
	Inventory	-10,264.32		-4,945.43	
	Current Investments	-		52.80	
	Trade Receivables	-434.82		4,895.03	
	Loans & Advances	-24.25		-45.66	
	Other Current Assets	-620.89		-748.13	
	Other Financial Assets	4,008.54		-6,777.03	
	Other Financial Assets	-1,349.52		-274.94	
	Trade Payables	3,485.04		3,858.26	
	Other Current Liabilities	642.21		1,472.79	
	Other Financial Liabilities	0.58		31.97	
	Short Term Provision	-954.00	-5,511.43	309.86	-2,170.48
			1,931.70		1,245.90
	INCREASE / DECREASE IN :-				
	LONG TERM PROVISIONS	-7.09		157.06	
			-7.09		157.06
	Net Cash Flow From Operating Activities		1,924.61		1,402.96
	Effects Of Changes In Non Current Items				-
	Other Non Current Assets		-		-
	Net Adjusted Cash Flow From Operating Activities		1,924.61		1,402.96

FREDUN PHARMACEUTICALS LTD. MUMBAI

Registered Office: Urmi Estate, 11th Floor, Ganpatrao Kadam Marg, Lower Parel (W), Mumbai - 400013.
Phone No.: 91-22- 4031 8111 Fax: 91-22-4031 8133
Factory: 14,15,16, Zorabian Industrial Complex, Vevoor, Palghar (E), Dist: Palghar - 401 404.
Phone No.: +917045957828, +917045957829, +917045957830, +917045956857
E-Mail: business@fredungroup.com Web: www.fredungroup.com

FREDUN PHARMACEUTICALS LIMITED

Compassionate Healthcare

CIN No : L24239MH1987PLC043662

	FREDUN PHARMACEUTICALS LIMITED				
	STANDALONE CASH FLOW STATEMENT FOR THE HALF YEAR ENDED 30th Sept, 2026				
		As at 30th Sept 2026		**As at 30th Sept 2025**	
		(Amount in Lakhs)		**(Amount in Lakhs)**	
B)	**Cash Flow From Investing Activities**				
	Purchase Of Fixed Assets	-3,836.81		-2,038.66	
	Sale Of Fixed Assets	15.55		-	
	Capital Work In Progress	-		-	
			-3,821.26		-2,038.66
			-1,896.65		-635.70
C)	**Cash Flow From Financing Activities**				
	Increase / Decrease In Issue Of Share Capital	16.05		-	
	Increase / Decrease In Issue Of Share Premium	1,990.61		-	
	Increase / Decrease In Issue Of Share Warrants	93.34		-	
	Increase / Decrease In Long Term Borrowings	3,062.37		1,924.96	
	Increase / Decrease In Short Term Borrowings	-600.57		1,427.48	
	Interest Received	26.26		-4.49	
	Interest Paid	-1,739.43		-1,426.30	
	Other Non Current Assets	-1,839.10		-443.64	
	Other Non Current Investments	-52.50		-92.45	
	Dividend Payout	-35.13		-	
			921.90		1,385.56
	Net Increase / Decrease In Cash		-974.74		749.86
	Opening Cash & Bank Balance		6,495.32		45.21
	Closing Cash & Bank Balance		5,520.58		795.07

For and on behalf of the Board of Directors of Fredun Pharmaceuticals Limited

CIN No - L24239MH1987PLC043662

For Fredun Pharmaceuticals Limited

FREDUN PHARMACEUTICALS LTD. MUMBAI

Place : Mumbai
Date : 05th November 2026

Dr. (Mrs) Daulat N. Medhora
Joint Managing Director
DIN : 01745277

Mr. Fredun N. Medhora
Managing Director & CFO
DIN : 01745348

Note:-

1 The above Cash Flow Statement has been prepared under the indirect method set out in the Indian Accounting Standard (Ind AS) - 7 on "Statement of Cash Flow".

2 Direct taxes paid are treated as arising from operating activities and not bifurcated between investing and financing activities.

3 Figures in Bracket sign indicate cash outflow.

4 Previous year figures have been regrouped & recast, wherever necessary, to conform to the current year's classification.

Registered Office: Urmi Estate, 11th Floor, Ganpatrao Kadam Marg, Lower Parel (W), Mumbai - 400013.
Phone No.: 91-22- 4031 8111 Fax: 91-22-4031 8133
Factory: 14,15,16, Zorabian Industrial Complex, Vevoor, Palghar (E), Dist: Palghar - 401 404.
Phone No.: +917045957828, +917045957829, +917045957830, +917045956857
E-Mail: business@fredungroup.com Web: www.fredungroup.com

R.H.Nisar & Co.

Chartered Accountant

A/501, Krushal Tower, M G Road, Near West Side, Chembur, Mumbai -400089
Contact No: 9867351724, Email – rakesh.nisar1@gmail.com

Independent Auditor's Review Report on Standalone Unaudited Quarterly Financial Results of the Company pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended)

To the Board of Directors of Fredun Pharmaceuticals Limited,

1. We have reviewed the accompanying statement of standalone unaudited financial results ('the Statement') of Fredun Pharmaceuticals Limited ('the Company') for the quarter ended 30th September 2026, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended) ('Listing Regulations').

2. The Statement, which is the responsibility of the Company's management and approved by the Company's Board of Directors on 05th November, 2026, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, Interim Financial Reporting ('Ind AS 34'), prescribed under section 133 of the Companies Act, 2013 ('the Act'), and other accounting principles generally accepted in India and is in compliance with the presentation and disclosure requirements of Regulation 33 of the Listing Regulations. Our responsibility is to express a conclusion on the Statement based on our review.

3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, Review of Interim Financial Information Performed by the Independent Auditor of the Entity, issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with the Standards on Auditing specified under section 143(10) of the Act, and consequently, does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.



R.H.Nisar & Co.
Chartered Accountant
A/501, Krushal Tower, M G Road, Near West Side, Chembur, Mumbai -400089
Contact No: 9867351724, Email – rakesh.nisar1@gmail.com

4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in Ind AS 34, prescribed under section 133 of the Act, and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in accordance with the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended), including the manner in which it is to be disclosed, or that it contains any material misstatement.

   Our conclusion on the statement is not modified in respect of the above matter.

FOR R H NISAR & CO.
CHARTERED ACCOUNTANTS
FIRM'S REGISTRATION NUMBER: 120895W





RAKESH NISAR
PROPRIETOR
MEMBERSHIP NO. 103659
UDIN: 26103659CBPFCW2224

PLACE: MUMBAI
DATE: 5th November, 2026

FREDUN PHARMACEUTICALS LIMITED

Compassionate Healthcare

CIN No : L24239MH1987PLC043662

UNAUDITED CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER & HALF YEAR ENDED 30.09.2026

		Consolidated					
		Quarter Ended			Half Year Ended		Year Ended
		Unaudited			Unaudited		Audited
	PARTICULARS	30.09.2026	30.06.2026	30.09.2025	30.09.2026	30.09.2025	31.03.2026
		Rs. In Lakhs	Rs. In Lakhs	Rs. In Lakhs	Rs. In Lakhs	Rs. In Lakhs	Rs. In Lakhs
1	**Income from Operations**						
	Net Sales /IncomeFrom Operation (Net of GST)	26585.37	22775.55	14358.53	49360.92	26298.82	63332.65
2	Other Operating Income	178.14	49.24	170.62	227.38	215.83	579.84
3	Total income from operatoins (net)	26763.51	22824.79	14529.15	49588.30	26514.65	63912.49
4	**Expenses**						
	a) Cost of Material Consumed	23981.10	17846.48	9925.76	41827.58	18958.38	48075.96
	b) Cost of Material Consumed for R & D	140.28	126.14	118.33	266.42	193.80	507.77
	c) Other R & D Expenses	0.00	0.00	0.00	0.00	0.00	0.00
	d) Changes in inventories of finished goods, work-in-progress and stock in trade	(4771.94)	(635.05)	441.28	(5406.99)	(224.86)	(3169.31)
	e) Manufacturing & Service Cost	448.70	407.35	366.13	856.05	730.04	1566.91
	f) Finance Costs	877.62	861.81	773.13	1739.43	1426.30	3929.76
	g) Employess benefits expenses	911.03	712.08	829.88	1623.11	1593.27	3294.34
	h) Depreciation and amortisation expenses	392.79	357.09	189.31	749.88	331.22	824.67
	i) Other Expenses	1818.83	1093.70	614.80	2912.53	1331.93	4182.77
	Total expenses	23798.41	20769.60	13258.62	44568.01	24340.08	59212.87
5	Profit/(Loss) from ordinary activities before exceptional items & tax (3-4)	2965.10	2055.19	1270.53	5020.29	2174.57	4699.60
6	Exceptional items / Prior Period Item	0.00	0.00	0.00	0.00	0.00	0.00
7	Profit/(Loss) from ordinary activities before tax (5-6)	2965.10	2055.19	1270.53	5020.29	2174.57	4699.60
8	Tax Expenses	1107.69	741.96	327.36	1849.65	554.82	1437.51
9	Profit/(Loss) from continuing operations	1857.42	1313.23	943.17	3170.65	1619.75	3262.09
10	Profit/(Loss) from discontinued operations	0.00	0.00	0.00	0.00	0.00	0.00
11	Tax Expense of discontinued operations	0.00	0.00	0.00	0.00	0.00	0.00
12	Profit/(Loss) from discontinued operations after tax	0.00	0.00	0.00	0.00	0.00	0.00
13	Profit/ (Loss) for the period	1857.42	1313.23	943.17	3170.65	1619.75	3262.09
14	Other comprehensive Income						
	A (i) Items that will not be re-classified to profit/ loss	0.00	0.00	0.00	0.00	0.00	0.00
	(ii) Income tax relating to items that will not be re-classified to profit/ loss	0.00	0.00	0.00	0.00	0.00	0.00
	B (i) Re measurement of post - employment benefit obligations	0.00	0.00	0.00	0.00	0.00	16.95
	C (i) Items that will be re-classified to profit / loss	0.00	0.00	0.00	0.00	0.00	0.00
	(ii) Income tax relating to items that will be re-classified to profit/ loss	0.00	0.00	0.00	0.00	0.00	0.00
	Total Comprehensive Income for the year	1857.42	1313.23	943.17	3170.65	1619.75	3279.04

FREDUN PHARMACEUTICALS LTD. MUMBAI

Registered Office: Urmi Estate, 11th Floor, Ganpatrao Kadam Marg, Lower Parel (W), Mumbai - 400013.
Phone No.: 91-22- 4031 8111 Fax: 91-22-4031 8133
Factory: 14,15,16, Zorabian Industrial Complex, Vevoor, Palghar (E), Dist: Palghar - 401 404.
Phone No.: +917045957828, +917045957829, +917045957830, +917045956857
E-Mail: business@fredungroup.com Web: www.fredungroup.com

FREDUN PHARMACEUTICALS LIMITED

Compassionate Healthcare

CIN No : L24239MH1987PLC043662

	PARTICULARS	Consolidated					
		Quarter Ended			Half Year Ended		Year Ended
		Unaudited			Unaudited		Audited
		30.09.2026	30.06.2026	30.09.2025	30.09.2026	30.09.2025	31.03.2026
		Rs. In Lakhs	Rs. In Lakhs	Rs. In Lakhs	Rs. In Lakhs	Rs. In Lakhs	Rs. In Lakhs
15	Paid up Equity Share Capital (Face Value of Rs-10/- each)	1689.97	1653.81	1416.51	1689.97	1416.51	1641.81
16	Reserves excluding Revaluation Reserves	0.00	0.00	0.00	0.00	0.00	0.00
17	Earning per Share (EPS) (before & after extra ordinary items)						
	- Basic/ Diluted Earning Per Share (Rs.)	10.99	7.94	19.98	18.76	11.43	19.97
	- Diluted Earning Per Share (Rs.)	10.92	7.84	0	18.64		19.57
A	1) Public Shareholding						
	Number of shares	9528510	3055637	2411277	9528510	2411277	3055637
	Percentage of shareholding	56.38%	55.43%	51.07%	56.38%	51.07%	55.83%
	2) Promoters and promotor group shareholding						
	a) Pledged/Encumbured						
	- Number of shares	-	-	-	-	-	-
	- Percentage of shares (as a % of total shareholding of Promoters and Prompter Group)	-	-	-	-	-	-
	- Percentage of shares (as a % of total share capital of the Company)	-	-	-	-	-	-
	b) Non-encumbered						
	- Number of shares	7371159	2457053	2310385	7371159	2310385	2417053
	- Percentage of shares (as a % of total shareholding of Promoters and Prompter Group)	43.62%	44.57%	49%	43.62%	49%	44.17%
	- Percentage of shares (as a % of total share capital of the Company)	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%

NOTES:-

1 The above unaudited Stardalone financial results which are published in accordance with Regulation 33 of the SEBI {Listing Obligations & Disclosure Requirements) Regulations, 2015 have been reviewed by the Audit Committee and approved by the Board of Directors at their respective meetings held on November 05, 2026. These unaudited Standalone financial results have been prepared in accordance with recognition and measurement principles of Indian Accounting Standards {"Ind AS") as prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and the other accounting principles generally accepted in India.

2 The above unaudited Standalone Financial results for the quarter ended September 30, 2026 are prepared in compliance with the Ind AS which have been subjected to a limited review by the statutory auditors of the Company. The statutory auditors, Rakesh Nisar & Co have issued limited review reports with unmodified conclusion on the standalone and consolidated unaudited financial results.

3 As the Company's business activity falls within a single operating segment viz "Pharmaceutical and Healthcare", no segment

4 The figures for the quarter ended Sept 30, 2026 are the balancing figures between audited figures in respect of the full financial year and the published year to date unaudited figures upto the third quarter of the previous financial year.

5 The figures for the earlier periods have been regrouped/ reclassified wherever necessary to make them comparable with those of the current

6 The above results were reviewed and recommended by the Audit Committee, for approval by the Board, at its meeting held on November 05, 2026 and were approved and taken on record at the meeting of the Board of Directors of the company held on that date

7 During the period, the Company allotted 11025380 fully paid-up bonus equity shares of ₹10 each in the ratio of two equity shares for every one equity share held, on 16.07.2026. Accordingly, basic and diluted earnings per share for all comparative periods presented have been retrospectively adjusted in accordance with Ind AS 33, "Earnings per Share." Earnings per share for the quarterly and half-yearly periods are not annualised.

8 During the half-year, the Company allotted 160533 equity shares pursuant to conversion of 160533 warrants, against receipt of the applicable consideration. The resulting increase in paid-up equity share capital has been reflected in these results. Basic and diluted earnings per share have been calculated considering the applicable weighted-average shares and dilutive potential equity shares.

PLACE: MUMBAI

DATE : 05th November , 2026

FOR FREDUN PHARMACEUTICALS LIMITED

Dr. (Mrs) DAULAT N. MEDHORA
Chair Person & Joint Managing Director
DIN :01745277

FREDUN PHARMACEUTICALS LTD. MUMBAI

Registered Office: Urmi Estate, 11th Floor, Ganpatrao Kadam Marg, Lower Parel (W), Mumbai - 400013.
Phone No.: 91-22- 4031 8111 Fax: 91-22-4031 8133
Factory: 14,15,16, Zorabian Industrial Complex, Vevoor, Palghar (E), Dist: Palghar - 401 404.
Phone No.: +917045957828, +917045957829, +917045957830, +917045956857
E-Mail: business@fredungroup.com Web: www.fredungroup.com

FREDUN PHARMACEUTICALS LIMITED

Compassionate Healthcare

CIN No : L24239MH1987PLC043662

FREDUN PHARMACEUTICALS LIMITED

Consolidated Balance Sheet for the Half Year Ended 30 Sept, 2026 **(Rs. In Lakhs)**

			As at 30 Sept, 2026	As at 31 March, 2026
I	**ASSETS**			
	NON-CURRENT ASSETS			
	a)	Property, Plant and Equipment	15,183.55	11,762.87
	b)	Capital Work-in-Progress	-	-
	c)	Other Intangible Assets	69.62	63.20
	d)	Financial assets		
		i) Investments	253.23	200.73
		ii) Loans	-	-
		iii) Other Financial Assets	2,945.52	1,596.00
	e)	Other Non-current Assets	2,649.10	767.78
	f)	Goodwill	-	-
		Total non - current assets	**21,101.02**	**14,390.57**
	CURRENT ASSETS			
	a)	Inventories	37,252.76	26,980.45
	b)	Financial Assets		
		i) Trade and other receivables	9,703.33	9,268.52
		ii) Cash and Cash Equivalents	5,530.87	6,492.66
		iii) Bank Balance other than (iii) above	5.92	5.40
		iv) Loans	122.76	87.55
		v) Other Financial Assets	1,487.31	5,455.49
	c)	Other Current Assets	2,153.71	1,527.59
		Total current assets	**56,256.67**	**49,817.66**
		TOTAL ASSESTS	**77,357.69**	**64,208.23**
II	**EQUITY AND LIABILITIES**			
	EQUITY			
	a)	Equity share capital	1,689.97	547.27
	b)	Other equity	31,352.86	27,263.50
	c)	Non-Controlling Interest	-0.01	-0.01
		Total Equity	**33,042.82**	**27,810.76**
	LIABILITIES			
	Non-Current Liabilities			
	a)	Financial liabilities		
		i) Borrowings	8,693.39	5,631.03
	b)	Provisions	418.46	425.55
	c)	Deferred Tax Liability	1,127.45	654.80
		Total non current - liabilities	**10,239.30**	**6,711.37**
	Current Liabilities			
	a)	Financial liabilities		
		i) Borrowings	16,580.16	16,609.03
		ii) Trade and other payable	12,263.12	8,758.27
		iii) Other financial liabilities	5.43	4.85
	b)	Other current liabilities	3,904.08	3,359.88
	d)	Current tax liabilities (net)	1,322.79	954.07
		Total current liabilities	**34,075.57**	**29,686.10**
		TOTAL EQUITY & LIABILITIES	**77,357.69**	**64,208.23**

For and on behalf of the Board of Directors of Fredun Pharmaceuticals Limited

CIN No - L24239MH1987PLC043662
For Fredun Pharmaceuticals Limited

FREDUN PHARMACEUTICALS LTD. MUMBAI

MR. Fredun N. Medhora
Managing Director & CFO
DIN :01745348

Dr. (Mrs) Daulat N.Medhora
Joint Managing Director
DIN : 01745277

Place - Mumbai
Date :- 05th November 2026

Registered Office: Urmi Estate, 11th Floor, Ganpatrao Kadam Marg, Lower Parel (W), Mumbai - 400013.
Phone No.: 91-22- 4031 8111 Fax: 91-22-4031 8133
Factory: 14,15,16, Zorabian Industrial Complex, Vevoor, Palghar (E), Dist: Palghar - 401 404.
Phone No.: +917045957828, +917045957829, +917045957830, +917045956857
E-Mail: business@fredungroup.com Web: www.fredungroup.com

FREDUN PHARMACEUTICALS LIMITED

Compassionate Healthcare

CIN No : L24239MH1987PLC043662

FREDUN PHARMACEUTICALS LIMITED

CONSOLIDATED CASH FLOW STATEMENT FOR THE HALF YEAR ENDED 30th Sept, 2026

	As at 30th Sept 2026 (Amount in Lakhs)		As at 30th Sept 2025 (Amount in Lakhs)	
A) CASH FLOW FROM OPERATING ACTIVITIES:				
NET PROFIT AFTER TAXATION		3,170.65		1,619.74
ADJUSTMENTS FOR :				
DEPRECIATION	749.42		331.22	
INTEREST PAID	1,739.43		1,426.30	
INTEREST RECEIVED	-26.26		4.49	
CREDITORS WRITTEN BACK	-68.49		-	
		2,394.10		1,762.01
		5,564.75		3,381.75
ADJUSTMENT TO OPERATING PROFIT				
DEFFERED TAX LIABILITY		472.65		-34.08
ADJUSTMENT FOR TAX PROVISION		1,377.00		-
OPERATING PROFIT BEFORE WORKING CAPITAL CHANGES		7,414.40		3,347.67
EFFECTS OF CHANGES IN WORKING CAPITAL ITEMS				
INCREASE / DECREASE IN :-				
INVENTORY	-10,272.31		-4,945.43	
TRADE RECEIVABLES	-434.81		4,895.03	
LOANS & ADVANCES	-35.21		-45.66	
OTHER CURRENT ASSETS	-626.12		-749.40	
OTHER FINANCIAL ASSETS	3,968.18		-6,777.32	
OTHER FINANCIAL ASSETS	-1,349.52		-274.94	
TRADE PAYABLES	3,504.85		3,861.26	
OTHER CURRENT LIABILITIES	544.20		1,539.88	
OTHER FINANCIAL LIABILITIES	0.58		31.96	
PROVISION FOR TAX	-954.00		309.86	
		-5,654.16	-	-2,154.76
		1,760.24		1,192.91
INCREASE / DECREASE IN :-				
LONG TERM PROVISIONS	-7.09		157.06	
		-7.09		157.06
NET CASH FLOW FROM OPERATING ACTIVITIES		1,753.15		1,349.97
EFFECTS OF CHANGES IN NON CURRENT ITEMS				-
OTHER NON CURRENT ASSETS		-		-
NET ADJUSTED CASH FLOW FROM OPERATING ACTIVITIES		1,753.15		1,349.97

FREDUN PHARMACEUTICALS LTD. MUMBAI

Registered Office: Urmi Estate, 11th Floor, Ganpatrao Kadam Marg, Lower Parel (W), Mumbai - 400013.
Phone No.: 91-22- 4031 8111 Fax: 91-22-4031 8133
Factory: 14,15,16, Zorabian Industrial Complex, Vevoor, Palghar (E), Dist: Palghar - 401 404.
Phone No.: +917045957828, +917045957829, +917045957830, +917045956857
E-Mail: business@fredungroup.com Web: www.fredungroup.com

FREDUN PHARMACEUTICALS LIMITED

Compassionate Healthcare

CIN No : L24239MH1987PLC043662

Consolidated Cash Flow for the Half Year Ended 30 Sept, 2026

	As at 30th Sept 2026 (Amount in Lakhs)		As at 30th Sept 2025 (Amount in Lakhs)	
B) CASH FLOW FROM INVESTING ACTIVITIES				
PURCHASE OF FIXED ASSETS	-4,186.31		-2,073.61	
SALE OF FIXED ASSETS	15.55		-	
		-4,170.76		-2,073.61
		-2,417.61		-723.64
C) CASH FLOW FROM FINANCING ACTIVITIES				
INCREASE / DECREASE IN ISSUE OF SHARE CAPITAL	16.05		-	
Increase / Decrease In Issue Of Share Premium	1,990.61		-	
Increase / Decrease In Issue Of Share Warrants	93.34		-	
INCREASE / DECREASE IN LONG TERM BORROWINGS	3,062.36		1,924.95	
INCREASE / DECREASE IN SHORT TERM BORROWINGS	-28.87		1,464.48	
OTHER NON CURRENT ASSETS	-1,876.36		-443.64	
OTHER NON CURRENT INVESTMENTS	-52.50		-38.65	
INTEREST RECEIVED	26.26		-4.49	
INTEREST PAID	-1,739.43		-1,426.31	
Dividend Payout	-35.13		-	
		1,456.33		1,476.34
NET INCREASE / DECREASE IN CASH		-961.28		752.71
OPENING CASH & BANK BALANCE		6,498.07		45.21
CLOSING CASH & BANK BALANCE		5,536.79		797.92

Place - Mumbai
Date :- 05th November, 2026

For Fredun Pharmaceuticals Limited

Mr. Fredun N. Medhora
Managing Director & CFO
DIN : 01745348

FREDUN PHARMACEUTICALS LTD. MUMBAI

Note:-

1 The above Cash Flow Statement has been prepared under the indirect method set out in the Indian Accounting Standard (Ind AS) - 7 on "Statement of Cash Flow".

2 Direct taxes paid are treated as arising from operating activities and not bifurcated between investing and financing activities.

3 Figures in Bracket sign indicate cash outflow.

4 Previous year figures have been regrouped & recast, wherever necessary, to conform to the current year's classification.

Registered Office: Urmi Estate, 11th Floor, Ganpatrao Kadam Marg, Lower Parel (W), Mumbai - 400013.
Phone No.: 91-22- 4031 8111 Fax: 91-22-4031 8133
Factory: 14,15,16, Zorabian Industrial Complex, Vevoor, Palghar (E), Dist: Palghar - 401 404.
Phone No.: +917045957828, +917045957829, +917045957830, +917045956857
E-Mail: business@fredungroup.com Web: www.fredungroup.com

R.H.Nisar & Co.

Chartered Accountant

A/501, Krushal Tower, M G Road, Near West Side, Chembur, Mumbai -400089
Contact No: 9867351724

Independent Auditor's Review Report on Consolidated Unaudited Quarterly Financial Results of the Company pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended)

To the Board of Directors of Fredun Pharmaceuticals Limited,

1. We have reviewed the accompanying statement of consolidated unaudited financial results ('the Statement') of Fredun Pharmaceuticals Limited ('the Parent') and its subsidiaries (the Parent and its subsidiaries together referred to as "the Group") for the quarter ended 30th September 2026, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended) ('Listing Regulations').

2. The Statement, which is the responsibility of the Company's management and approved by the Parent's Board of Directors on 05th November, 2026, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, Interim Financial Reporting ('Ind AS 34'), prescribed under section 133 of the Companies Act, 2013 ('the Act'), and other accounting principles generally accepted in India and is in compliance with the presentation and disclosure requirements of Regulation 33 of the Listing Regulations. Our responsibility is to express a conclusion on the Statement based on our review.

3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, Review of Interim Financial Information Performed by the Independent Auditor of the Entity, issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with the Standards on Auditing specified under section 143(10) of the Act, and consequently, does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

   We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33 (8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended, to the extent applicable.



R.H.Nisar & Co.

Chartered Accountant

A/501, Krushal Tower, M G Road, Near West Side, Chembur, Mumbai -400089
Contact No: 9867351724

4. The statement includes the results of the following entities:

   Incorporated in India

   a. Fredun Retail Private Limited
   b. One Pet Stop Private Limited
   c. Wagr Retail Private Limited

5. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in Ind AS 34, prescribed under section 133 of the Act, and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in accordance with the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended), including the manner in which it is to be disclosed, or that it contains any material misstatement.

   Our conclusion on the statement is not modified in respect of the above matter.

FOR R H NISAR & CO.
CHARTERED ACCOUNTANTS
FIRM'S REGISTRATION NUMBER: 120895W





RAKESH NISAR
PROPRIETOR
MEMBERSHIP NO. 103659
UDIN: 26103659PCHMYX9863

PLACE: MUMBAI
DATE: 05th November, 2026